Archive | November, 2017

Associations between medical cannabis and prescription opioid use in chronic pain patients: A preliminary cohort study.

PLoS One. 2017 Nov 16;12(11):e0187795. doi: 10.1371/journal.pone.0187795. eCollection 2017. Vigil JM1, Stith SS2, Adams IM3, Reeve AP3. Author information Abstract BACKGROUND: Current levels and dangers of opioid use in the U.S. warrant the investigation of harm-reducing treatment alternatives. PURPOSE: A preliminary, historical, cohort study was used to examine the association between enrollment in the New […]

Legalization of Recreational Marijuana and Community Sales Policy in Oregon: Impact on Adolescent Willingness and Intent to Use, Parent Use, and Adolescent Use.

Psychol Addict Behav. 2017 Nov 16. doi: 10.1037/adb0000327. [Epub ahead of print] Rusby JC, Westling E, Crowley R, Light JM. Abstract Studies investigating the impact of medical marijuana legalization have found no significant changes in adolescent use. In one of the few studies focused on recreational marijuana, we investigated how recreational marijuana legalization and community […]

Assessment of Genetic Diversity and Population Structure in Iranian Cannabis Germplasm.

Sci Rep. 2017 Nov 15;7(1):15668. doi: 10.1038/s41598-017-15816-5. Soorni A1,2, Fatahi R1, Haak DC3, Salami SA4, Bombarely A5. Author information Abstract Cannabis sativa has a complex history reflected in both selection on naturally occurring compounds and historical trade routes among humans. Iran is a rich resource of natural population swhich hold the promise to characterize historical […]

Treating a novel plasticity defect rescues episodic memory in Fragile X model mice.

Mol Psychiatry. 2017 Nov 14. doi: 10.1038/mp.2017.221. [Epub ahead of print] Wang W1, Cox BM1, Jia Y1, Le AA1, Cox CD1, Jung KM1, Hou B1, Piomelli D1,2,3, Gall CM1,4, Lynch G1,5. Author information Abstract Episodic memory, a fundamental component of human cognition, is significantly impaired in autism. We believe we report the first evidence for […]


Am J Physiol Endocrinol Metab. 2017 Nov 14:ajpendo.00119.2017. doi: 10.1152/ajpendo.00119.2017. [Epub ahead of print] Gandhi K1, Li C2, German N1, Skobowiat C3, Carrillo M1, Kallem RR1, Larumbe E1, Martinez S1, Chuecos M1, Ventolini G1, Nathanielsz P2, Schlabritz-Loutsevitch N4. Author information Abstract INTRODUCTION: Involvement of endogenous cannabinoids (eCBs) in obesity is well-characterized. However, information regarding eCB […]

Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: A survey of the status in the chapters of the European Pain Federation.

Eur J Pain. 2017 Nov 13. doi: 10.1002/ejp.1147. [Epub ahead of print] Krcevski-Skvarc N1,2, Wells C3, Häuser W4,5. Author information Abstract BACKGROUND: There is considerable public and political interest in the use of cannabis products for medical purposes. METHODS: The task force of the European Pain Federation (EFIC) conducted a survey with its national chapters […]

Cannabinoid Receptor Type 1 Agonist ACEA Protects Neurons from Death and Attenuates Endoplasmic Reticulum Stress-Related Apoptotic Pathway Signaling.

Neurotox Res. 2017 Nov 13. doi: 10.1007/s12640-017-9839-1. [Epub ahead of print] Vrechi TA1, Crunfli F1, Costa AP1, Torrão AS2. Author information Abstract Neurodegeneration is the result of progressive destruction of neurons in the central nervous system, with unknown causes and pathological mechanisms not yet fully elucidated. Several factors contribute to neurodegenerative processes, including neuroinflammation, accumulation […]

Medical cannabis Q&A

Journal List >Can Pharm J (Ott) > v.150(6); Nov-Dec 2017 > PMC5661684 Can Pharm J (Ott). 2017 Nov-Dec; 150(6): 353–354. Published online 2017 Oct 5. doi:  10.1177/1715163517735811 PMCID: PMC5661684 Medical cannabis Q&A Copyright and License information ► 1. What is medical cannabis? The term “medical cannabis” is used to describe products derived from the whole cannabis plant or its extracts containing […]

Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology.

Clin Pharmacol Drug Dev. 2017 Nov 10. doi: 10.1002/cpdd.408. [Epub ahead of print] Atsmon J1, Heffetz D2, Deutsch L3, Deutsch F3, Sacks H2. Author information Abstract Cannabidiol (CBD) is the main nonpsychoactive component of the cannabis plant. It has been associated with antiseizure, antioxidant, neuroprotective, anxiolytic, anti-inflammatory, antidepressant, and antipsychotic effects. PTL101 is an oral […]

Involvement of cannabinoid receptor type 2 in light-induced degeneration of cells from mouse retinal cell line in vitro and mouse photoreceptors in vivo.

Exp Eye Res. 2017 Nov 10. pii: S0014-4835(16)30445-6. doi: 10.1016/j.exer.2017.11.003. [Epub ahead of print] Imamura T1, Tsuruma K2, Inoue Y1, Otsuka T1, Ohno Y1, Ogami S3, Yamane S3, Shimazawa M1, Hara H1. Author information Abstract Earlier studies showed that the expressions of the agonists of the cannabinoid receptors are reduced in the vitreous humor of […]